Literature DB >> 28869666

Comprehensive Guidance for Antibiotic Dosing in Obese Adults.

Lina Meng1,2, Emily Mui1,2, Marisa K Holubar2,3, Stan C Deresinski2,3.   

Abstract

Physiologic alterations seen in obesity commonly impact the pharmacokinetics (PK) and pharmacodynamics (PD) of antibiotics and may result in suboptimal dosing in this expanding but understudied population. Much of the published clinical and PK evidence to date consists of small patient populations and are retrospective with, not infrequently, heterogeneous results that in some cases are contradictory. In the last 10 years, additional antimicrobial PK/PD and clinical data encompassing prolonged infusion strategies and examination of critically ill populations have emerged to inform antimicrobial dosing in obesity. In this narrative review, we critically review literature on dosing, PK, and possible dosing strategies in obese adults. We searched PubMed, Scopus, and the Cochrane Library using Medical Subject Headings including anti-infectives, specific antimicrobial names, obese, pharmacokinetics, and others. We reviewed articles, cross-referenced select cited references, and when applicable, referenced drug databases and package inserts to develop dosing recommendations. We provide an overall critical review of the available data regarding PK and dosing issues including dosing recommendations in both critically ill and noncritically ill patients with significant obesity. We developed dosing recommendations for 34 antimicrobials based on 121 articles of the 2336 identified by the search strategy. Although 11 of these do not appear to require dose adjustment, obesity-specific dosing guidance is provided for the remaining 23 antimicrobials. Additional studies are needed to better understand and resolve discrepant published results regarding the PK of antibiotics to establish optimal dosing strategies in obese adults. Alternative dosing strategies, such as extended infusions, should be considered for time-dependent antibiotics (e.g., β-lactams) in obese patients to achieve PD targets reliably. Therapeutic drug monitoring across the spectrum of antimicrobials is of increasing importance in this and other populations to ensure optimized dosing.
© 2017 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  antibiotic; antimicrobial; critically ill; dosing; obesity; pharmacokinetics

Mesh:

Substances:

Year:  2017        PMID: 28869666     DOI: 10.1002/phar.2023

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  25 in total

1.  A rare case of Campylobacter rectus pyogenic extensor tenosynovitis.

Authors:  James B Doub
Journal:  Germs       Date:  2021-12-29

2.  High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients.

Authors:  D Busse; P Simon; D Petroff; N El-Najjar; L Schmitt; D Bindellini; A Dietrich; M Zeitlinger; W Huisinga; R Michelet; H Wrigge; C Kloft
Journal:  Antimicrob Agents Chemother       Date:  2022-05-23       Impact factor: 5.938

3.  Vancomycin dosing in an obese patient with acute renal failure: A case report and review of literature.

Authors:  Kun-Yan Xu; Dan Li; Zhen-Jie Hu; Cong-Cong Zhao; Jing Bai; Wen-Li Du
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

4.  Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.

Authors:  David Busse; Philipp Simon; Lisa Schmitt; David Petroff; Christoph Dorn; Arne Dietrich; Markus Zeitlinger; Wilhelm Huisinga; Robin Michelet; Hermann Wrigge; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2021-12-11       Impact factor: 5.577

Review 5.  Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam.

Authors:  Jianguo Li; Mark Lovern; Todd Riccobene; Timothy J Carrothers; Paul Newell; Shampa Das; Angela K Talley; Margaret Tawadrous
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 6.  Pharmacokinetic/Pharmacodynamic Considerations of Beta-Lactam Antibiotics in Adult Critically Ill Patients.

Authors:  Anne M Masich; Mojdeh S Heavner; Jeffrey P Gonzales; Kimberly C Claeys
Journal:  Curr Infect Dis Rep       Date:  2018-04-04       Impact factor: 3.725

7.  Evaluation of a modified vancomycin nomogram for obese adults.

Authors:  Nathan Batchelder; Carrie Faith Lutheran; Jeremy Frens
Journal:  Eur J Clin Pharmacol       Date:  2019-12-13       Impact factor: 2.953

Review 8.  Optimizing antimicrobial use: challenges, advances and opportunities.

Authors:  Timothy M Rawson; Richard C Wilson; Danny O'Hare; Pau Herrero; Andrew Kambugu; Mohammed Lamorde; Matthew Ellington; Pantelis Georgiou; Anthony Cass; William W Hope; Alison H Holmes
Journal:  Nat Rev Microbiol       Date:  2021-06-22       Impact factor: 60.633

Review 9.  Antimicrobial Dosing in Specific Populations and Novel Clinical Methodologies: Obesity.

Authors:  Manjunath P Pai
Journal:  Clin Pharmacol Ther       Date:  2021-02-28       Impact factor: 6.875

10.  Clinical Outcomes with Ertapenem for Pneumonia in Obese versus Nonobese Patients.

Authors:  Ryan Caputo; Alan Rozycki; Megan McClain; M Mahdee Sobhanie; Kelci Coe; Nora Colburn; Lynn Wardlow
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.